What the FDA labels say about taking them together
Everolimus and fosamprenavir
Fosamprenavir's FDA label of September 15, 2023 names everolimus in its drug interactions section; the everolimus labels PlainMeds reads (2) do not name fosamprenavir. The fosamprenavir label: “Fosamprenavir or fosamprenavir/ritonavir may increase plasma concentrations of antineoplastics metabolized by CYP3A, potentially increasing the risk of adverse events typically associated with these medications. …”
Check it at the source: the everolimus FDA label on DailyMed (effective June 1, 2026, Novartis Pharmaceuticals Corporation); the fosamprenavir FDA label on DailyMed (effective September 15, 2023, Mylan Pharmaceuticals Inc.).
What does the everolimus label say about fosamprenavir?
Everolimus's label (effective June 1, 2026) and its 1 other brand-application label do not name fosamprenavir in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Afinitor), Novartis Pharmaceuticals Corporation, effective June 1, 2026 (SPL set 2150f73a-179b-4afc-b8ce-67c85cc72f04), via openFDA; the full label on DailyMed
What does the fosamprenavir label say about everolimus?
Fosamprenavir label, drug interactionsConcomitant Drug Class/Drug Name: Antineoplastics: Dasatinib, nilotinib, ibrutinib, vinblastine, everolimus; Effect on Concentration of Amprenavir or Concomitant Drug: ↑ Antineoplastics; Clinical Comment: Fosamprenavir or fosamprenavir/ritonavir may increase plasma concentrations of antineoplastics metabolized by CYP3A, potentially increasing the risk of adverse events typically associated with these medications. In case of coadministration, please refer to relevant prescribing information for these medications.
Source: FDA drug label (Fosamprenavir Calcium), Mylan Pharmaceuticals Inc., effective September 15, 2023 (SPL set 3a1424d8-844c-4e24-9ebd-b2c2b61b61a3), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Everolimus | Fosamprenavir | |
|---|---|---|
| Labeled for | Breast cancer, Seizures and epilepsy, Organ transplant rejection | HIV |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $26.32 per tablet 10 mg tablet | n/a |
| Shortage now | A presentation being discontinued | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once